1. Home
  2. OSW vs PHVS Comparison

OSW vs PHVS Comparison

Compare OSW & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpaWorld Holdings Limited

OSW

OneSpaWorld Holdings Limited

HOLD

Current Price

$28.20

Market Cap

2.4B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.01

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSW
PHVS
Founded
2017
2015
Country
Bahamas
Switzerland
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
OSW
PHVS
Price
$28.20
$34.01
Analyst Decision
Strong Buy
Buy
Analyst Count
4
11
Target Price
$27.00
$41.82
AVG Volume (30 Days)
802.3K
331.1K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
0.81%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$961,001,000.00
N/A
Revenue This Year
$7.49
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
$129.81
N/A
Revenue Growth
7.37
N/A
52 Week Low
$19.06
$16.72
52 Week High
$29.25
$35.33

Technical Indicators

Market Signals
Indicator
OSW
PHVS
Relative Strength Index (RSI) 69.73 64.43
Support Level $19.70 $24.73
Resistance Level N/A N/A
Average True Range (ATR) 1.16 1.61
MACD 0.27 0.19
Stochastic Oscillator 82.98 71.94

Price Performance

Historical Comparison
OSW
PHVS

About OSW OneSpaWorld Holdings Limited

OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: